rs2271194 — ERBB3 ERBB3/RAB5B PCOS Metabolic

A splice-region variant at the ERBB3/RAB5B locus on chromosome 12q13.2, a replicated PCOS susceptibility region; the A allele tags coordinated dysregulation of EGF receptor signalling, vesicular trafficking, and androgen co-repression in ovarian theca cells, increasing PCOS susceptibility with additive metabolic risk

See your personal result for ERBB3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ERBB3/RAB5B — A Metabolic-Reproductive Crossroads at Chromosome 12q13.2

One of the most intriguing PCOS susceptibility loci is not a single gene but a functional cluster on chromosome 12q13.2, where three seemingly distinct biological processes converge: EGF receptor signalling, vesicular membrane trafficking, and androgen transcriptional regulation. The rs2271194 variant is an intronic/splice-region tag SNP within ERBB3/HER311 ERBB3/HER3
Erb-b2 receptor tyrosine kinase 3; a member of the epidermal growth factor receptor family that forms obligate heterodimers with ERBB2 to amplify growth factor signalling and, uniquely among the ErbB family, lacks intrinsic kinase activity, on a haplotype that has been associated with PCOS in large European cohorts and that contains RAB5B22 RAB5B
Ras-related protein Rab-5B; a small GTPase regulating early endosomal biogenesis and receptor internalisation and recycling after ligand binding and PA2G4 as co-located candidates.

The Mechanism

The functional picture at 12q13.2 is multifactorial, involving at least three interacting mechanisms identified through exome sequencing of PCOS theca cells and single-cell RNA sequencing:

Vesicular trafficking (RAB5B): In normal theca cells, stimulation with forskolin (a proxy for LH/cAMP signalling) upregulates RAB5B — the early endosomal GTPase that controls receptor recycling and downstream signalling duration. Harris et al. 202533 Harris et al. 2025
Multimodal integration of genomic data at the PCOS-associated 12q13.2 locus. Int J Mol Sci 26 showed that this upregulation is specifically impaired in PCOS theca cells, reducing the cells' ability to correctly internalise and recycle signalling receptors — including the insulin receptor and ERBB family members — after ligand activation. A complementary paper found that the enhancer variant rs1081975 at this locus shows perfect colocalization with RPS26/RAB5B/SUOX eQTLs (posterior probability 1.0), confirming RAB5B expression is directly regulated from this haplotype.

Androgen co-repression (PA2G4/ERBB3 interaction): The locus also encodes PA2G4 (ErbB3 binding protein 1), a transcriptional co-repressor of the androgen receptor. Harris et al. 202344 Harris et al. 2023
Loci on chromosome 12q13.2 encompassing ERBB3, PA2G4 and RAB5B are associated with PCOS. Gene 853:147059 demonstrated that PA2G4 interacts physically with the ERBB3 cytoplasmic domain, and that a PA2G4 promoter SNV in the associated haplotype drives markedly reduced PA2G4 expression in PCOS theca cells (padj = 3.82×10⁻³⁰ after forskolin). Because PA2G4 is a corepressor of androgen receptor activity, its reduction releases androgen receptor signalling from normal suppression, contributing to the excess androgen production that defines PCOS.

ERBB3 expression: In normal theca cells, ERBB3 is downregulated by cAMP/forskolin stimulation. The 12q13.2 haplotype appears to alter this regulatory response, contributing to aberrant EGF receptor activity in PCOS cells.

The Evidence

The chromosome 12q13.2 locus was first identified in a Han Chinese GWAS: Shi et al. 201255 Shi et al. 2012
Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 44:1020–1025 analysed 8,226 PCOS cases and 7,578 controls, identifying 12q13.2 among eight newly significant loci, with candidate genes enriched for insulin signalling, sexual hormone function, and type 2 diabetes pathways. The rs2271194-A allele specifically reached genome-wide significance in the largest European PCOS GWAS: Day et al. 201866 Day et al. 2018
Large-scale GWAS meta-analysis of PCOS suggests shared genetic architecture. PLoS Genet 14:e1007813 meta-analysed 10,074 PCOS cases and 103,164 European controls, confirming rs2271194-A (beta 0.0971, SE 0.0166, p=5×10⁻⁹) among replicated PCOS loci. Mendelian randomization in the same dataset demonstrated causal associations with higher insulin resistance (P=6×10⁻⁴) and lower SHBG — a finding directly relevant to the 12q13.2 locus's enrichment for insulin signalling candidates.

The protein-level relevance of ERBB3 was confirmed by colocalization analysis: Censin et al. 202177 Censin et al. 2021
Colocalization analysis of PCOS to identify potential disease-mediating genes and proteins. Eur J Hum Genet 29:1096–1104 found that ERBB3 protein QTLs co-localize with PCOS genetic signals with posterior probability consistent with a shared causal variant, placing ERBB3 among seven proteins explaining roughly 30% of known PCOS signals.

Notably, a 2025 cross-trait analysis found that ERBB3 also emerges as a central shared gene between PCOS and asthma, both of which show inflammatory and hormonal dysregulation involving EGF receptor pathways — suggesting the 12q13.2 locus may have broader pleiotropic effects beyond reproductive phenotypes.

Practical Actions

The 12q13.2 locus is specifically enriched for insulin signalling pathways, making metabolic monitoring and insulin-sensitising interventions especially relevant for women carrying the risk A allele. Unlike the purely reproductive DENND1A locus, this locus connects directly to insulin resistance, making it a metabolic-reproductive PCOS subtype. Myo-inositol acts as a second messenger in the insulin/FSH signalling cascade and has specific evidence for improving ovarian insulin sensitivity in PCOS. Spearmint tea has documented anti-androgenic activity via LH/FSH modulation. Monitoring free testosterone and HOMA-IR (insulin resistance index) captures both arms of this locus's biology.

Interactions

ERBB3 is one of three EGF receptor family members (alongside ERBB2 and ERBB4) with PCOS associations. The rs2271194 (ERBB3) and rs2178575 (ERBB4) loci mark distinct chromosomal regions and likely contribute independently to PCOS risk. Combined risk allele burden across ERBB family loci may amplify follicular signalling deficits, though published compound effect sizes do not exist for this combination. The RAB5B impairment in vesicular trafficking may also amplify insulin receptor dysregulation in women co-carrying rs7852296 (DENND1A) risk alleles, as both pathways converge on receptor internalisation and recycling in theca cells.

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-risk Genotype Normal

No elevated PCOS risk from this ERBB3/RAB5B locus variant

You carry two copies of the T allele at rs2271194, the most common genotype globally (approximately 33% of people). This genotype is not associated with elevated PCOS susceptibility from the ERBB3/RAB5B locus. The T allele is the majority allele in European, East Asian, and South Asian populations. Overall PCOS risk depends on many factors beyond this single locus — including the DENND1A, LHCGR, THADA, and ERBB4 susceptibility variants.

AT One Risk Allele Intermediate

One copy of the ERBB3/RAB5B risk allele — modestly elevated PCOS susceptibility

The chromosome 12q13.2 locus was independently identified as a PCOS susceptibility region in both Han Chinese (Shi et al. 2012) and European (Day et al. 2018) GWAS datasets, confirming its transethnic validity. The biological mechanism is multifactorial: impaired RAB5B response to cAMP signalling disrupts receptor recycling, a PA2G4 promoter variant reduces androgen receptor corepression, and altered ERBB3 expression affects EGF pathway activity in theca cells. The A allele frequency varies substantially by ancestry — it is more common in African populations (~64%) than in East Asian ones (~22%), which likely reflects population-specific PCOS prevalence patterns.

As a heterozygous carrier, one haplotype copy is affected; the overall risk elevation per allele is quantified at beta 0.0971 on the log-OR scale (approximately OR 1.10 per allele). Combining this with other PCOS risk variants at DENND1A, LHCGR, ERBB4, and THADA loci determines overall polygenic burden.

AA Two Risk Alleles High Risk

Two copies of the ERBB3/RAB5B risk allele — elevated PCOS susceptibility with metabolic component

The Day et al. 2018 meta-analysis established rs2271194-A as a genome-wide significant PCOS risk allele (beta 0.0971 per copy, p=5×10⁻⁹) in 10,074 PCOS cases and 103,164 European controls. Under additive scaling, the AA genotype carries approximately twice the per-allele risk contribution (~beta 0.194 on the log-OR scale, approximately OR 1.21 vs TT). The 12q13.2 locus was originally identified by Shi et al. 2012 in a Han Chinese cohort enriched for insulin signalling and type 2 diabetes candidate genes — making metabolic co-morbidity screening particularly important for AA carriers.

The mechanistic basis involves: (1) impaired RAB5B upregulation after LH/cAMP stimulation in PCOS theca cells, disrupting insulin receptor and EGF receptor recycling; (2) reduced PA2G4 expression, releasing androgen receptor from normal transcriptional repression; and (3) altered ERBB3/EGF receptor activity in the theca cell microenvironment. The co-localization of ERBB3 protein QTLs with PCOS GWAS signals (Censin et al. 2021) supports direct protein-level involvement.

Unlike some PCOS loci that are purely reproductive, the 12q13.2 locus's connection to insulin signalling means AA carriers should be monitored for both the reproductive manifestations (cycle irregularity, elevated androgens, PCOS morphology) and metabolic ones (insulin resistance, dyslipidaemia, elevated risk of type 2 diabetes in the context of PCOS).